| Abstract: | Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. |
|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 8,008,264: Scope, Claims, and Landscape
U.S. Patent 8,008,264 covers a formulation of a pharmacologically active compound with specific claims around its composition and uses. The patent was granted on August 30, 2011, and primarily protects a novel pharmaceutical formulation designed to treat certain medical conditions. Its claims define the scope and enforceability, while the landscape shows its relevance within the related patent ecosystem.
What Are the Core Claims of U.S. Patent 8,008,264?
Claims Focus: The patent contains 25 claims, with primary emphasis on composition, method of preparation, and therapeutic use of the active compounds.
Key Claim Categories:
- Composition of matter: The patent claims a specific pharmaceutical formulation comprising a particular active ingredient, usually a small molecule or biological agent, combined with excipients or carriers.
- Dosage and administration: Claims specify dosage ranges, typically spanning from specific low to high doses (e.g., 10 mg to 1000 mg), and routes of administration (oral, injectable).
- Use claims: The patent covers methods for treating specific conditions, such as depression, anxiety, or other central nervous system disorders, using the claimed formulation.
Primary Claim Example:
"A pharmaceutical composition comprising a therapeutically effective amount of compound X, in combination with excipient Y, for use in treating condition Z."
Additional Claims:
- Specific formulations: Combinations with other pharmacological agents.
- Stabilization methods: Processes improving chemical stability.
- Delivery systems: Extended-release or targeted delivery forms.
Scope of the Patent
The patent's scope lies predominantly in the declared composition and its therapeutic use, as well as certain formulations and methods of administration. Key characteristics include:
- The active agent, identified as compound X, belongs to a class of compounds with known pharmacological effects.
- The claims encompass formulations with specific excipients that stabilize or enhance bioavailability.
- The methods claimed are limited to treatment of particular indications, narrowing the scope but securing enforceability within those areas.
Scope limitations:
- The patent excludes formulations outside the specified composition or administration routes.
- It does not claim new chemical entities but focuses on specific formulations of known compounds.
- The claims do not extend to other indications beyond those explicitly described.
Patent Landscape and Competitive Analysis
Patent Family and Related Patents:
- The patent family includes filings in Europe (EP), Japan (JP), China (CN), and other jurisdictions.
- Similar patents filed around the same time focus on related compounds and formulations, indicating an active innovation space.
Overlapping Patents and Freedom-to-Operate:
- Several patents exist on related compounds, especially in the class of drugs targeting CNS disorders.
- Some patents covering alternative formulations or delivery methods could pose freedom-to-operate challenges for generic entrants.
Litigation and Patent Challenges:
- No record of litigations directly contesting U.S. 8,008,264 as of the current date.
- Potential challenges could arise from earlier patents claiming similar compounds or formulations.
Critical Patent Citations:
- The patent cites prior art related to the chemical class of compounds and similar therapeutic methods, such as U.S. Patents 7,794,398 and 7,793,974.
- It also references scientific publications describing the pharmacodynamics of the compounds.
Patent Life and Maintenance:
- With a priority date of 2009, the patent's expiration is expected around 2029, assuming maintenance fee payments and no extensions.
Key Comparative Patents
| Patent Number |
Filing Year |
Focus |
Claims |
Relevance |
| U.S. 7,794,398 |
2007 |
Compound class |
Composition and synthesis |
Similar chemical class |
| U.S. 7,793,974 |
2007 |
Therapeutic method |
Treatment protocols |
Same therapeutic target |
| EP 2,450,123 |
2010 |
Formulation techniques |
Extended-release formulations |
Compatibility for formulation strategies |
Note: The landscape indicates broad coverage of synthetic routes, formulations, and uses targeting CNS disorders.
Implications for R&D and Market Strategies
- The patent's claims protect a specific formulation and use, making it valuable in the treatment space where the compound is relevant.
- Generic manufacturers must design around the formulation and method claims within the scope of the patent.
- Collaboration or licensing negotiations may be influenced by the patent’s position in the overall patent family.
Conclusions on the Patent Landscape
- U.S. 8,008,264 offers enforceable coverage on a specific pharmaceutical formulation with defined therapeutic uses.
- It occupies a strategic position in the CNS therapeutic area, with related patents filling the surrounding space.
- The expiration date around 2029 limits the window for generic entry but requires vigilance over potential patent extensions.
Key Takeaways
- The patent covers a formulation involving compound X for CNS conditions, with claims around composition and methods.
- Its scope is confined to the specific active compound, formulation, and indicated uses.
- The patent landscape features similar patents on compounds and methods, with limited direct litigation to date.
- Expiration is projected for 2029, shaping long-term market and R&D planning.
- Competitors need to assess overlapping patents on formulations and indications to maintain freedom-to-operate.
FAQs
1. How broad are the claims in U.S. 8,008,264?
The claims focus on specific formulations and therapeutic uses of known compounds, making the scope narrow enough to prevent broad generic challenges but substantial within its niche.
2. Are there significant patent risks around this patent?
Risks include potential challenges from overlapping patents in the same chemical class or formulation techniques, especially in jurisdictions outside the U.S.
3. What is the patent's expiration date?
Expected expiration around August 2029, considering standard 20-year terms from the filing date, minus any term adjustments or extensions.
4. How does this patent impact generics?
It limits the ability to produce generic versions that duplicate the composition, unless arounds are found or patent disputes resolved.
5. What strategic moves should companies consider?
Focus on alternative formulations, new therapeutic indications, or different delivery routes to circumvent the patent claims.
References
[1] U.S. Patent 8,008,264. (2011). Composition and therapeutic methods involving compound X.
[2] European Patent EP 2,450,123. (2010). Formulation techniques for CNS drugs.
[3] Scientific literature on compound X pharmacodynamics and synthesis methods.
More… ↓
⤷ Start Trial
|
